Original articlesUncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain
Abstract
In vivo assessment of the beta-sheet proteins deposited in amyloid plaques (Aβ peptide) or neurofibrillary tangles (tau protein) presents a target for the development of biological markers for Alzheimer's disease (AD). In an effort to develop in vivo beta-sheet imaging probes, derivatives of thioflavin-T (ThT) were synthesized and evaluated. These compounds lack the positively charged quaternary heterocyclic nitrogen of ThT and are therefore uncharged at physiological pH. They are 600-fold more lipophilic than ThT. These ThT derivatives bind to Aβ(1-40) fibrils with higher affinity (Ki = 20.2 nM) than ThT (Ki = 890 nM). The uncharged ThT derivatives stained both plaques and neurofibrillary tangles in post-mortem AD brain, showing some preference for plaque staining. A carbon-11 labeled compound, [N-methyl-11C]6-Me-BTA-1, was prepared, and its brain entry and clearance were studied in Swiss-Webster mice. This compound entered the brain at levels comparable to commonly used neuroreceptor imaging agents (0.223 %ID-kg/g or 7.61 %ID/g at 2 min post-injection) and showed good clearance of free and non-specifically bound radioactivity in normal rodent brain tissue (brain clearance t1/2 = 20 min). The combination of relatively high affinity for amyloid, specificity for staining plaques and neurofibrillary tangles in post-mortem AD brain, and good brain entry and clearance makes [N-methyl-11C]6-Me-BTA-1 a promising candidate as an in vivo positron emission tomography (PET) beta-sheet imaging agent.
References (0)
Cited by (418)
In vitro evaluation of [<sup>3</sup>H]PI-2620 and structural derivatives in non-Alzheimer's tauopathies
2024, Nuclear Medicine and BiologyAlzheimer's disease (AD) and non-AD tauopathies such as chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) are characterized by the abnormal aggregation of three-repeat (3R) and/or four-repeat (4R) tau isoforms. Several tau-PET tracers have been applied for human imaging of AD and non-AD tauopathies including [18F]PI-2620. Our objective is to evaluate [3H]PI-2620 and two promising structural derivatives, [3H]PI-2014 and [3H]F-4, using in vitro saturation assays and competitive binding assays against new chemical entities based on this scaffold in human AD tissues for comparison with PSP, CBD and CTE tissues. Thin section autoradiography was employed to assess specific binding and distribution of [3H]PI-2620 and [3H]F-4 in fresh-frozen human post-mortem AD, PSP, CBD and CTE tissues. Immunohistochemistry was performed for phospho-tau (AT8) and 4R-tau (RD4). Homogenate filtration binding assays were performed for saturation analysis and competitive binding studies against [3H]PI-2620. All compounds bound with high affinity in AD tissue. In PSP tissue [3H]PI-2620 demonstrated the highest affinity (5.3 nM) and in CBD tissue [3H]F-4 bound with the highest affinity (9.4 nM). Over 40 fluorinated derivatives based on PI-2620 and F-4 were screened in AD and PSP tissue. Notably, compound 2 was the most potent derivative in PSP tissue (Ki = 7.3 nM). By autoradiography, [3H]PI-2620 and [3H]F-4 demonstrated positive signals similar in intensity in AD, PSP and CTE tissues that were displaced by homologous blockade. Binding of both radiotracers aligned with immunostaining for 4R-tau. This work demonstrates that [3H]PI-2620 and [3H]F-4 show promise for imaging 4R-tau aggregates in non-AD tauopathies. PI-2620 continues to serve as a structural scaffold for PET radiotracers with higher affinity for non-AD tau over AD tau.
Dicyano-derivatives as mapping agents for peripheric Aβ plaques in Alzheimer's disease mouse model
2024, Results in ChemistryAbnormal accumulation amyloid-β (Aβ) is recognized as one of the crucial factors for the progression and pathology of AD, which has accelerated the development of new chemical agents or technology for early mapping and monitoring Aβ plagues. While Aβ plaques is from diffuse to highly compacted (dense-core), most of reported dyes or probes could only stain the core of Aβ, due to the lack of monitoring technology, the research on periphery of Aβ was always ignored. Herein, we reported a new near-infrared (NIR) fluorescent probe named Dicyano-3, which had the capability to stain both core and periphery of Aβ plaques. Dicyano-3 was based on dicayno-scaffold and input N,N’-dimethyl group connecting with double bond. Meanwhile, cyclopropyl group applied in drug discovery was introduced to the structure which could lead to good photophysical properties. Dicyano-3 displayed good binding affinity for Aβ aggregates and better histological staining capability compared to Thioflavin T. Furthermore, Dicyano-3 showed good blood–brain barrier (BBB) permeability and low cytotoxicity. More importantly, in vivo imaging results indicate that the fluorescent intensity in the brain in 10-month APP/PS1 mice is higher than age-matched wild type mice. We believe that Dicyano-3 is benefit for the research of Aβ mechanism and AD drug discovery.
Effects of microwave on the structural and emulsifying properties and interfacial properties of oxidized soybean protein aggregates
2023, Food Chemistry: XThis research explored microwave treatment impact on the structuro-functional aspects of oxidized soy protein aggregates (OSPI). Data showed that oxidative treatment promoted the formation of high molecular weight aggregates through hydrophobic interactions, thereby disrupting the structure of natural soy protein isolates (SPI). Microwave treatment for an appropriate time (≤30 s) caused the molecular structure of OSPI to open up and reduction in molecular weight and disulfide bond content, while absolute zeta potential increased. These modifications increased emulsifying capacity of OSPI, as well as the interfacial adsorption of protein. Longer microwave treatment times (>30 s) caused OSPI to exhibit a tendency to aggregate in TEM and CLSM images. It indicated the appropriate microwave electromagnetic field effect and microwave heating effect could coordinatively regulate soy protein functional properties by modifying their aggregation behavior. The results provided new ideas for reducing resource waste, and further expanding soy protein application in the food industry.
Direct visualization of β-amyloid fibrils with a self-powered imaging strategy through the generation of fluorescent tags with Pt nanozymes
2023, Chemical Engineering JournalAggregation of β-amyloid (Aβ) peptides plays a critical role in the pathogenesis of Alzheimer’s disease (AD). Visualizing Aβ1-40 aggregates is therefore essential for the understanding of pathological mechanisms. However, labeling Aβ aggregates with regular fluorophores commonly suffers from poor photostability, low photobleaching resistance, and high background noise. In this work, we introduce a self-powered imaging (SPI) strategy by using Pt nanoparticles (PtNPs) as the nanozymes to catalyze the generation of fluorescent resorufin (Rf) as efficient fluorescent tags for Aβ1-40 aggregates imaging. Since the catalytic event is randomized at the single-molecule level, nanoscopic imaging of Aβ1-40 aggregates is successfully realized through the single-molecule localization microscopy. The inhibitory effect of photosensitizers on Aβ1-40 fibrillation process is therefore imaged with nanoscale resolution. The SPI strategy introduced herein provides a promising catalysis-based method for Aβ1-40 fibrillation imaging.
Small-molecule theranostics in Alzheimer's disease
2023, European Journal of Medicinal ChemistryAlzheimer's Disease (AD) remains one of the most challenging health-related issues for our society. It is becoming increasingly prevalent, especially in developed countries, due to the rising life expectancy and, moreover, represents a considerable economic burden worldwide. All efforts at the discovery of new diagnostic and therapeutic tools in the last decades have invariably met with failure, making AD an incurable illness and underscoring the need for new approaches. In recent years, theranostic agents have emerged as an interesting strategy. They are molecules able to simultaneously provide diagnostic information and deliver therapeutic activity, allowing for the assessment of the molecule activity, the organism response and the pharmacokinetics. This makes these compounds promising for streamlining research on AD drugs and for their application in personalized medicine. We review here the field of small-molecule theranostic agents as promising tools for the development of novel diagnostic and therapeutic resources against AD, highlighting the positive and significant impact that theranostics can be expected to have in the near future in clinical practice.
Leveraging the regulatory framework to facilitate drug development in Parkinson's disease
2023, Handbook of Clinical NeurologyThere is an exigent need for disease-modifying and symptomatic treatment approaches for Parkinson's disease. A better understanding of Parkinson's disease pathophysiology and new insights in genetics has opened exciting new venues for pharmacological treatment targets. There are, however, many challenges on the path from discovery to drug approval. These challenges revolve around appropriate endpoint selection, the lack of accurate biomarkers, challenges with diagnostic accuracy, and other challenges commonly encountered by drug developers. The regulatory health authorities, however, have provided tools to provide guidance for drug development and to assist with these challenges. The main goal of the Critical Path for Parkinson's Consortium, a nonprofit public–private partnership part of the Critical Path Institute, is to advance these so-called drug development tools for Parkinson's disease trials. The focus of this chapter will be on how the health regulators’ tools were successfully leveraged to facilitate drug development in Parkinson's disease and other neurodegenerative diseases.